Schrödinger, Inc.

NasdaqGS:SDGR

Sector

🤖 Technology

Industries

🔬 Clinical Trials

🤖 Artificial Intelligence (AI)

📊 Big Data

🧬 Biotechnology

💻 Software & Operating Systems

Location

United States

Market Cap

USD 1.54 B

Share Price

USD 20.46

Avg Daily Volume

1,199,093

Change (1 day)

-2.80%

Change (1 year)

7.97%

Change (YTD)

6.07%

Schrödinger, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -82.96%

Schrödinger, Inc. EBT Margin is -82.96% for the Trailing 12 Months (TTM) ending March 31, 2025, a -6.28% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Schrödinger, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -88.52%, a -527.07% change year over year.
Schrödinger, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 20.73%, a -123.74% change year over year.
Schrödinger, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -87.29%, a 692.57% change year over year.
Schrödinger, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -11.01%, a -70.83% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBT Margin	Operating Income Margin	Gross Profit Margin	EBIT Margin

NasdaqGS: SDGR

Schrödinger, Inc.

CEO	Dr. Ramy Farid Ph.D.
IPO Date	Feb. 6, 2020
Location	United States
Headquarters	1540 Broadway
Employees	891
Sector	🤖 Technology
Industries Clinical Trials 🤖 Artificial Intelligence (AI) 📊 Big Data 🧬 Biotechnology 💻 Software & Operating Systems

Description

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.